Evidence map›Paper›PMID 40713244›Full record

ReviewThe journal of prevention of Alzheimer's disease2025

Disclosure of Alzheimer's disease blood-based biomarker results in a primary care setting: Opportunities and challenges.

Corey J Bolton, Ayda Rostamzadeh, Nathaniel Chin, Nicole R Fowler, Judith Heidebrink, Annalise Rahman-Fillipiak, Raymond R Romano, Lindsay R Clark, Advisory Group on Risk Evidence Education in Dementia (AGREEDementia)

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The journal of prevention of Alzheimer's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Corey J BoltonVanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN 37203, USA; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address: corey.bolton@vumc.org.
Ayda RostamzadehDepartment of Psychiatry, University of Cologne, Medical Faculty, Cologne 50931, Germany.
Nathaniel ChinWisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, WI 53792, USA; Department of Medicine, Division of Geriatrics & Gerontology, University of Wisconsin School of Medicine and Public Health, University of Wisconsin - Madison, Madison, WI 53792, USA.
Nicole R FowlerDepartment of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA; Indiana University Center for Aging Research, Indianapolis, IN 46202, USA.
Judith HeidebrinkDepartment of Neurology, University of Michigan, Ann Arbor, MI 48109, USA; Michigan Alzheimer's Disease Center, University of Michigan, Ann Arbor, MI 48109, USA.
Annalise Rahman-FillipiakMichigan Alzheimer's Disease Center, University of Michigan, Ann Arbor, MI 48109, USA; Research Program on Cognition & Neuromodulation Based Interventions, Department of Psychiatry, University of Michigan, Ann Arbor, MI 48109, USA.
Raymond R RomanoVanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN 37203, USA; Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Lindsay R ClarkWisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, WI 53792, USA; Department of Medicine, Division of Geriatrics & Gerontology, University of Wisconsin School of Medicine and Public Health, University of Wisconsin - Madison, Madison, WI 53792, USA; Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, 53792, USA.
Advisory Group on Risk Evidence Education in Dementia (AGREEDementia)

Funding

Behavioral Change Following Culturally-Informed Biomarker Disclosure in Alzheimer’s DiseaseK23AG070044 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RAHMAN-FILIPIAK, ANNALISE · 2021 to 2025
$914k
NIA NIH HHS K23 AG070044
6 · The paper itself

Abstract

Blood-based biomarkers (BBMs) for Alzheimer's disease (AD) have advanced rapidly and may be a critical tool for broad community-based screening for AD and detection of AD pathology in individuals with cognitive impairment. To meet the impending demand for AD diagnosis, BBMs could be implemented in a primary care setting to maximize accessibility and efficiency. However, this primary care implementation would be associated with numerous challenges, including issues related to disclosure of test results to patients. In this perspective article, we highlight the need for and potential challenges of AD BBM results disclosure in a primary care setting. Drawing from existing studies of AD risk disclosure, we highlight key areas of consideration to maximize patient safety and comprehension of results. Resources are suggested to aid health systems in implementing BBM testing in primary care settings. Finally, we emphasize the need for further research on the accuracy of BBMs and the practice of disclosure in primary care settings.

Indexed as

Alzheimer DiseaseBiomarkersDisclosurePrimary Health CareHumansBiomarkersAlzheimer's diseaseBlood-based biomarkersDisclosurePrimary careP-tau217

Identifiers

PMID40713244
PMCPMC12501330

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.